$DRNA News
Last published 2y ago
- 2y agoALGSHAENVOPLRX+2Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies
- 3y agoDRNAA Study of DCR-STAT3 in Adults With Solid Tumors - NCT06098651ClinicalTrials.govIncidence of adverse events and dose limiting toxicities, Severity of adverse events, Pharmacokinetic (AUC), Pharmacokinetic (Urine)
- 4y agoDRNANovo Nordisk Announces Completion of Dicerna Pharmaceuticals AcquisitionBusiness WireNovo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. ((Dicerna, NASDAQ:DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has
- 4y agoDRNADicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire DicernaBusiness WireDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Novo Nordisk's cash tender offer for Dicerna expired at 11:59 p.m.
- 4y agoALNYARWRBGNEBNTX+6Direxion Launches mRNA ETF (MSGR)PR NewswireNEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR). MSGR invests in companies believed to be at the forefront of the development and application of messenger RNA technology. The MSGR ETF
- 4y agoDRNAAn Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD) - NCT05146882ClinicalTrials.govThe incidence of treatment-emergent adverse events, The change from baseline in pulmonary function tests (PFTs), The change from baseline in PFTs, (and 11 more...)
- 4y agoASPCDRNAROGVGMoore Kuehn Encourages ASPC, ROG, DRNA, and VG Investors to Contact Law FirmGlobeNewswireNEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair t
- 4y agoCALADRNAMRAAS+1Thinking about buying stock in Dicerna Pharmaceuticals, Cloopen Group, Calithera Biosciences, ZTO Express, or Macy's?PR NewswireNEW YORK, Nov. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRNA, RAAS, CALA, ZTO, and M. To s
- 4y agoDRNANovo Nordisk to Acquire DicernaBusiness Wire– Acquisition to Accelerate and Expand Novo Nordisk Development of RNAi Therapeutics Using Dicerna's Proprietary GalXC™ Technology Platform – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that it has entered into a definitive agre
- 5y agoDRNADicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With LillyBusiness Wire– Milestone Triggers Two Single-Digit Multimillion-Dollar Payments to Dicerna – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly
- 5y agoDRNADicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021Business Wire– Belcesiran Was Shown to Be Safe and Well Tolerated in Phase 1 Trial and Demonstrated Robust, Dose-Dependent Reductions in Serum Alpha-1 Antitrypsin – – Enrollment in ESTRELLA Phase 2 Study of Belcesiran Is Ongoing; Global Rollout to Additio
- 5y agoDRNADicerna Announces Third Quarter 2021 Financial Results and Provides a Business UpdateBusiness Wire– Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol
- 5y agoDRNADicerna Pharmaceuticals, Inc (DRNA) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsDRNA earnings call for the period ending September 30, 2021.
- 5y agoDRNADicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021Business Wire– Nedosiran Achieved Primary Endpoint Demonstrating Statistically Significant Sustained Reduction in Urinary Oxalate Excretion and Showed Robust Efficacy in PH1 – – Real-World Healthcare Utilization Data Showed Delayed Diagnosis in More Than
- 5y agoDRNADicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021Business WireDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2021 financial results be
- 5y agoDRNADicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)Business Wire– Study Met Primary Safety Endpoint; Nedosiran Shown to be Generally Safe and Well Tolerated in Patients With PH3 – – Although Trial Did Not Meet Prespecified Secondary Efficacy Endpoint, Data Showed Encouraging Trends in Urinary Oxalate Reduct
- 5y agoDRNADicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021Business Wire– Data From PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria (PH) Accepted as Late-Breaker Poster Presentation – – Company on Track to Submit Nedosiran New Drug Application (NDA) to the U.S. Food and Drug Administrati
- 5y agoDRNADicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in NovemberBusiness WireDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that two abstracts related to the Company's clinical development programs have been accepted for poste
- 5y agoDRNADicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors appro
- 5y agoDRNADicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use DisorderBusiness Wire– Trial to Evaluate Safety and Tolerability of DCR-AUD in Healthy Volunteers – – Trial Includes Ethanol Interaction Assessments to Evaluate Participants' Response to Alcohol After Receiving DCR-AUD – Dicerna Pharmaceuticals, Inc. (NASDAQ:D
- 5y agoDRNADicerna Announces New Executive Leadership AppointmentsBusiness Wire– Rob Ciappenelli Appointed Chief Strategy Officer and Marc Abrams, Ph.D., Promoted to Senior Vice President of Discovery Research – – Kristen Sheppard, Esq., Joins Company as Senior Vice President of Investor Relations and Corporate Communicat
- 5y agoDRNADicerna to Participate in 16th Annual Citi Biopharma ConferenceBusiness WireDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer,
- 5y agoDRNAPhase 1 SAD Study of DCR-AUD in Healthy Volunteers - NCT05021640ClinicalTrials.govIncidence and severity of AEs, SAEs, and DLTs as assessed by CTCAE v5.0., Number of participants with abnormalities in vital signs, electrocardiogram (ECG), and clinically significant laboratory findings., Plasma area under the concentration curve (AUC)., (and 8 more...)
- 5y agoDRNANedosiran in Pediatric Patients From Birth to 5 Years of Age With PH and Relatively Intact Renal Function - NCT05001269ClinicalTrials.govEfficacy: Percent change in urinary oxalate to creatinine ratio, Efficacy: Absolute change in urinary oxalate to creatinine ratio, Safety: Incidence of Events, (and 23 more...)
- 5y agoDRNADicerna Pharmaceuticals, inc (DRNA) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsDRNA earnings call for the period ending June 30, 2021.
- 5y agoDRNADicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021Business WireDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2021 financial results b
- 5y agoDRNADicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use DisorderBusiness Wire– Novel ALDH2-Targeting GalXC™ RNAi Candidate Designed to Address a Highly Prevalent and Undertreated Disorder1 – – Dicerna Expects to Initiate Phase 1 Clinical Trial of DCR-AUD in the Third Quarter of 2021 – Dicerna Pharmaceuticals, Inc
- 5y agoDRNADicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors appro
- 5y agoDRNADicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver DiseaseBusiness WireDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced it has initiated patient dosing in the Company's Phase 2 ESTRELLA trial of belc
- 5y agoDRNADicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3Business Wire– Company Continues to Expect Nedosiran New Drug Application Submission in Fourth Quarter of 2021 – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RN
- 5y agoDRNADicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare ConferenceBusiness WireDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer,
- 5y agoDRNADicerna Announces FDA Acceptance of Lilly's Investigational New Drug (IND) Application for LY3819469Business Wire– Second GalXC™ RNAi Investigational New Drug (IND) Application Filed by Lilly Under Companies' Global Research Collaboration and Licensing Agreement – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading develope
- 5y agoDRNADicerna Announces Boehringer Ingelheim's Acceptance of Candidate for Development Under RNAi Research Collaboration and License AgreementBusiness WireDevelopment Candidate Will Be Evaluated for Treatment of Nonalcoholic Steatohepatitis Candidate Selection Triggers Single-Digit Multimillion USD Milestone Payment to Dicerna Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"),
- 5y agoDRNADicerna to Participate in Upcoming Investor ConferencesBusiness WireDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer,
- 5y agoDRNADicerna Announces First Quarter 2021 Financial Results and Provides a Business UpdateBusiness Wire– Announced Sale of OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million; Extends Cash Runway Into 2024 – – Earned $25 Million Milestone Payment in Connection With Roche's Initiation of GalXC™ RNAi Candidate RG6346
- 5y agoDRNADicerna Pharmaceuticals, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time. To listen to the event live or a
- 5y agoDRNADicerna Pharmaceuticals Inc (DRNA) Q1 2021 Earnings Call TranscriptEarnings Call TranscriptsDRNA earnings call for the period ending March 31, 2021.
- 5y agoDRNADicerna to Report First Quarter 2021 Financial Results on May 6, 2021Business WireDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2021 financial results af
- 5y agoRPRXDRNARoyalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 MillionGlobeNewswireDicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc...
- 5y agoDRNARPRXDicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 MillionBusiness WireLEXINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) and Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. OXLUMO, which has been approv ...
- 5y agoDRNADicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireLEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 31,875 shares of common stock and 7,125 restricte ...
- 5y agoDRNADicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical StudiesBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced new data from preclinical studies of its GalXC-Plus™ RNAi technology demonstrating its potential to deliver deep and sustained messenger RNA (mRNA) knockdown against prespecified gene ...
- 5y agoDRNADicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual CongressBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Maire Osborn, Ph.D., Associate Director of Neuro Discovery at Dicerna, will present new nonclinical data discussing the Company’s GalXC-Plus™ RNAi technology as part of the sixth ...
- 5y agoDRNADicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021Business WireLEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will host a webinar on its recently announced alcohol use disorder (AUD) candidate, DCR-AUD. The event will take place on March 18, 2021 at 4:30 p.m. ET.
- 5y agoDRNADicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus InfectionBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today that Roche has initiated RG6346 in a Roche-sponsored Phase 2 combination trial for the treatment of chronic hepatitis B virus (HBV) infection. RG6346 is an investigational GalXC™ RNAi ...
- 5y agoDRNADicerna Pharmaceuticals Inc (DRNA) Q4 2020 Earnings Call TranscriptEarnings Call TranscriptsDRNA earnings call for the period ending December 31, 2020.
- 5y agoDRNADicerna Announces Full Year 2020 Financial Results and Provides a Business UpdateBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the full year ended Dec. 31, 2020 and provided a corporate update.
- 5y agoDRNADicerna to Participate in Upcoming Investor ConferencesBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in the following upcoming investor conferences:
- 5y agoDRNADicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021Business WireLEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its financial results for the full year ended Dec. 31, 2020 after market close on Thursday, Feb. 25, 2021.
- 5y agoDRNADicerna Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3Business WireLEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced initiation of patient dosing in the Company’s PHYOX™4 clinical trial to assess its lead investigational candidate, nedosiran, for the treatment of primary hyperoxaluria (PH) type 3 (PH ...